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Background Tuberculosis (TB) remains the largest cause of death among people living with HIV/AIDS, especially among those with profound immunosuppression. Case-fatality among co-infected patients occurs mainly in the first months after the TB treatment initiation. Therefore, robust data regarding optimal timing of HAART initiation within this early period is critically needed. . Patients received standard 6-month TB treatment plus stavudine, lamivudine and efavirenz in 5 hospitals in Cambodia, 2 in Phnom Penh and 3 in province. Patients were followed for 50 weeks after the last patient's enrollment. A log-rank test was used to compare Kaplan-Meier survival curves.
Methods
Results 661 patients (early, n=332; late, n=329) were enrolled with a median age of 35 yrs, body mass index of 16.7 kg/m 2 , CD4+ cell count of 25 cells/mm 3 and viral load of 5.64 log copies/ml. All AFB-positive samples including sputum in 538 (81.4%) patients, were cultured. As of May 13, 2010, 149 patients were known dead (59, early arm; 90, late arm). Enhanced survival was observed in the early arm (p=0.004, see figure) . At week 50, median CD4+ gain was 114 cells/mm 3 and was not statistically different across arms (p=0.22); 96.5% of patients had an undetectable viral load and again no difference across arms was found (0.82). 
Conclusion
Initiation of HAART 2 weeks after onset of TB treatment significantly improves survival in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. 
